Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00298272 · ClinicalTrials.gov registry record · Phase 2
Safety and Tolerability of Rituxan With Methotrexate and Etanercept or Methotrexate and Adalimumab in Patients With Active Rheumatoid Arthritis
A Phase 2 study, sponsored by Biogen.
- Terminated
- Registry status
- Phase 2
- Development phase
- 54
- Enrollment target
NCT00298272 is a Phase 2 study that was terminated before completion, run by Biogen. The registered enrollment target is 54 participants.
The verdict
NCT00298272, a Phase 2 study, was terminated before completion, sponsored by Biogen.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 54 participants
- Enrollment target
Study Summary
The primary objective of this study was to evaluate the tolerability and safety of rituximab in combination with methotrexate (MTX) and etanercept or adalimumab in participants with active rheumatoid arthritis (RA). The secondary objective was to explore the efficacy of rituximab in combination with MTX and etanercept or adalimumab in participants with active RA.
Interventions
- DRUG Placebo
- DRUG Adalimumab
- DRUG Methotrexate
- DRUG Etanercept
- BIOLOGICAL IDEC-C2B8 (rituximab)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2006-05 |
| Est. Completion | 2011-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00298272
The ClinicalTrials.gov registry entry for NCT00298272 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT00298272 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00298272 about?
NCT00298272 is a clinical study titled "Safety and Tolerability of Rituxan With Methotrexate and Etanercept or Methotrexate and Adalimumab in Patients With Active Rheumatoid Arthritis". The primary objective of this study was to evaluate the tolerability and safety of rituximab in combination with methotrexate (MTX) and etanercept or adalimumab in participants with active rheumatoid arthritis (RA). The secondary objective was to explore the efficacy of rituximab in combination with...
What is the current status of trial NCT00298272?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 54 participants. The study started on 2006-05. Estimated completion is 2011-07.
What interventions are being tested in trial NCT00298272?
The interventions under investigation include: Placebo (DRUG), Adalimumab (DRUG), Methotrexate (DRUG), Etanercept (DRUG), IDEC-C2B8 (rituximab) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00298272?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.